Verde Servicos Internacionais S.A. Invests $1.84 Million in Eli Lilly and Company $LLY

Verde Servicos Internacionais S.A. purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the 1st quarter, Holdings Channel reports. The firm purchased 2,000 shares of the company’s stock, valued at approximately $1,840,000. Eli Lilly and Company makes up about 0.6% of Verde Servicos Internacionais S.A.’s portfolio, making the stock its 27th biggest holding.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Spire Wealth Management increased its stake in shares of Eli Lilly and Company by 2.2% during the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after purchasing an additional 592 shares during the last quarter. Coldstream Capital Management Inc. raised its holdings in shares of Eli Lilly and Company by 25.6% in the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after purchasing an additional 8,659 shares during the period. Farther Finance Advisors LLC lifted its stake in Eli Lilly and Company by 30.8% in the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after purchasing an additional 7,338 shares during the last quarter. Teachers Retirement System of The State of Kentucky lifted its stake in Eli Lilly and Company by 3.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock valued at $126,022,000 after purchasing an additional 5,595 shares during the last quarter. Finally, Stonebridge Capital Advisors LLC grew its holdings in Eli Lilly and Company by 318.1% during the third quarter. Stonebridge Capital Advisors LLC now owns 10,519 shares of the company’s stock worth $8,026,000 after purchasing an additional 8,003 shares during the period. 82.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on LLY shares. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Finally, Barclays lifted their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,230.89.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,115.98 on Thursday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm’s 50-day simple moving average is $1,026.17 and its 200 day simple moving average is $1,018.81. The firm has a market cap of $1.05 trillion, a price-to-earnings ratio of 39.64, a P/E/G ratio of 1.21 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the previous year, the firm posted $3.34 EPS. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly completed its acquisition of Centessa Pharmaceuticals, strengthening its sleep-wake disorder pipeline and adding orexin-based drug development assets. Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
• Positive Sentiment: The company announced a potential $1.9 billion research collaboration with Abbisko Therapeutics, expanding its global drug-discovery efforts and pipeline optionality. Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
• Positive Sentiment: Lilly said China approval for its GLP-1 obesity/diabetes pill could come as soon as later in 2026, reinforcing expectations for another major growth driver beyond Mounjaro and Zepbound. China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
• Positive Sentiment: Management also signaled a Europe launch strategy for the obesity pill, suggesting Lilly is preparing to expand its weight-loss franchise internationally as approvals progress. Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.